Publications by authors named "Panagiota Gkolfi"
Article Synopsis
- A study investigated the long-term survival benefits of adding lapatinib to chemotherapy and trastuzumab in HER2-positive early breast cancer, comparing rates of pathological complete response (pCR).*
-
- Over a ten-year follow-up, patients receiving the combination treatment showed event-free survival (EFS) rates of 67% and overall survival (OS) rates of 80%, with pCR linked to significantly better EFS and OS.*
-
- The findings indicate that neoadjuvant anti-HER2 therapy provides lasting survival advantages for patients, particularly for those achieving pCR, without any new safety issues reported.*
